Literature DB >> 12372334

Bombesin-dependent pro-MMP-9 activation in prostatic cancer cells requires beta1 integrin engagement.

Claudio Festuccia1, Adriano Angelucci, Giovanni Gravina, Enrica Eleuterio, Carlo Vicentini, Mauro Bologna.   

Abstract

Bombesin-like peptides, including the mammalian homologue gastrin-releasing peptide, are highly expressed and secreted by neuroendocrine cells in prostate carcinoma tissues and are likely to be related to the progression of this neoplastic disease. Previously, we demonstrated that bombesin increased migration and protease expression in androgen-independent cells. In this work we show that bombesin is able to activate pro-MMP-9 through a mechanism involving the beta1 integrin subunit. In fact, MMP-9 processing was evident only when beta1 integrin was engaged with specific adhesive substrates, such as type I collagen, or when cells were seeded on dishes coated with antibodies against beta1 integrin, resulting in activation of the surface ligand. When exogenous pro-MMP-9 was added to PC3 cells, MMP-9 active forms were produced within 30 min by bombesin-treated cultures while control cultures expressed activated forms only after a longer time and at lower levels. MMP-9 activation required cytoskeleton integrity since this effect was abolished by cytochalasin D. Engagement of beta1 integrin caused an increased membrane-linked uPA activity which was required for MMP-9 activation. The cross talk between bombesin- and beta1-integrin-engaged signals seems to be crucial for the modulation of both membrane-linked uPA activity and MMP-9 activation and triggers complex intracellular signaling pathways requiring activation of tyrosine kinase activity, including that of src and PI3K. The beta1 integrin may be considered an important mechanism by which bombesin induces MMP-9 activation. This finding supports the idea that cellular responses to growth factors may be driven by cell-matrix interactions and stresses the role of neuroendocrine factors in prostate carcinoma progression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12372334     DOI: 10.1006/excr.2002.5609

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  8 in total

Review 1.  Nonreceptor tyrosine kinases in prostate cancer.

Authors:  Yu-Ming Chang; Hsing-Jien Kung; Christopher P Evans
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

2.  Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer.

Authors:  Izabela Podgorski; Bruce E Linebaugh; Mansoureh Sameni; Christopher Jedeszko; Sunita Bhagat; Michael L Cher; Bonnie F Sloane
Journal:  Neoplasia       Date:  2005-03       Impact factor: 5.715

3.  Integrin β1 is critical for gastrin-releasing peptide receptor-mediated neuroblastoma cell migration and invasion.

Authors:  Sora Lee; Jingbo Qiao; Pritha Paul; Dai H Chung
Journal:  Surgery       Date:  2013-08       Impact factor: 3.982

4.  Specific antibodies elicited by a novel DNA vaccine targeting gastrin-releasing peptide inhibit murine melanoma growth in vivo.

Authors:  Jing Fang; Yong Lu; Kedong Ouyang; Guojun Wu; Huiyong Zhang; Yanhua Liu; Yingying Chen; Ming Lin; Huaqian Wang; Liang Jin; Rongyue Cao; Rouel S Roque; Li Zong; Jingjing Liu; Taiming Li
Journal:  Clin Vaccine Immunol       Date:  2009-05-20

5.  Coordinate regulation of estrogen-mediated fibronectin matrix assembly and epidermal growth factor receptor transactivation by the G protein-coupled receptor, GPR30.

Authors:  Jeffrey A Quinn; C Thomas Graeber; A Raymond Frackelton; Minsoo Kim; Jean E Schwarzbauer; Edward J Filardo
Journal:  Mol Endocrinol       Date:  2009-04-02

6.  Functional live-cell imaging demonstrates that beta1-integrin promotes type IV collagen degradation by breast and prostate cancer cells.

Authors:  Mansoureh Sameni; Julie Dosescu; Kenneth M Yamada; Bonnie F Sloane; Dora Cavallo-Medved
Journal:  Mol Imaging       Date:  2008 Sep-Oct       Impact factor: 4.488

7.  Comparative study of 64Cu/NOTA-[D-Tyr6,βAla11,Thi13,Nle14]BBN(6-14) monomer and dimers for prostate cancer PET imaging.

Authors:  Patrick Fournier; Véronique Dumulon-Perreault; Samia Ait-Mohand; Réjean Langlois; François Bénard; Roger Lecomte; Brigitte Guérin
Journal:  EJNMMI Res       Date:  2012-02-14       Impact factor: 3.138

8.  XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).

Authors:  Giovanni Luca Gravina; Monica Tortoreto; Andrea Mancini; Alessandro Addis; Ernesto Di Cesare; Andrea Lenzi; Yosef Landesman; Dilara McCauley; Michael Kauffman; Sharon Shacham; Nadia Zaffaroni; Claudio Festuccia
Journal:  J Hematol Oncol       Date:  2014-10-05       Impact factor: 17.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.